Abstract 1355
Background
Surgery in cirrhotic patients in malignancy provokes scepticism and pessimism among clinicians due to mortality rates as high as 25% . In our study we looked at morbidity and mortality associated with these patients and present a positive perspective.
Methods
A data analysis of patients with cirrhosis, who underwent surgery for non-hepatic malignancy during the period January 2011 to December 2016, was done. Child Turcot Pugh (CTP) and Model for End stage Liver Disease (MELD) scores, various intraoperative parameters, perioperative morbidity (Clavien Dindo classification), mortality and hospital stay were recorded.
Results
40 patients with cirrhosis underwent surgery for non-hepatic malignancy. Emergency surgery was done in 6 patients. 26 patients were CTP grade A, 13 patients were grade B and 11 patients had grade C. Mean MELD score was 9.5 ±4.2. Overall mean operating time was 4.6 ±2.4 hours and blood loss was 305 ± 150 ml. In these patients, median blood transfusion requirement was 2 (1-5) PRBC. Overall morbidity was 26% but major morbidity (Clavien Dindo III) was seen in 5 patients (12.5%). Perioperative mortality occurred in 2 patients (5%). Patients who underwent surgery in emergency had more morbidity (n = 2,33%) and mortality (n = 1,16%) (p = <0.001).
Conclusions
In cirrhotic patients who undergo surgery for non-hepatic malignancy the factors associated with poor outcomes are emergency surgery, higher CTP grade and MELD score irrespective of type of malignancy. In these patients meticulous perioperative management can lead to excellent results and we need to shun negative attitudes while formulating a management plan for them.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Saurabh Galodha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
905 - Dose distribution in coronary arteries in left-sided breast cancer treated with Radiotherapy
Presenter: Umesh Velu
Session: Poster display - Cocktail
Resources:
Abstract
1060 - Metabolic Syndrome in Luminal-Type Non-Metastatic Breast Cancer during Hormonal Treatment Does it really have impact on prognosis?
Presenter: Kartika Taroeno-Hariadi
Session: Poster display - Cocktail
Resources:
Abstract
1148 - High Eosinophils Lymphocyte Ratio (ELR) Related With Subtype of Breast Cancer in Sanglah General Hospital, Bali
Presenter: Anak Agung Lestari
Session: Poster display - Cocktail
Resources:
Abstract
400 - Ribociclib (RIB) + endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC)
Presenter: Norikazu Masuda
Session: Poster display - Cocktail
Resources:
Abstract
801 - Osteopontin Level and Promoter Polymorphism is Associated with Aggressiveness in Breast Cancer
Presenter: Mohamed Elbaiomy
Session: Poster display - Cocktail
Resources:
Abstract
1014 - Global Clinical Trials Validating Bioequivalence with China-Manufactured Trastuzumab Biosimilar, HLX02, and Herceptin®
Presenter: Quanying Zhang
Session: Poster display - Cocktail
Resources:
Abstract
1138 - Circular RNA NCAPG promotes breast cancer metastasis through acting as the sponge of miR-200s
Presenter: Yunjie He
Session: Poster display - Cocktail
Resources:
Abstract
145 - Repeat biopsy a must in recurrent breast cancer: A study from tertiary cancer centre in India.
Presenter: Abhishek Anand
Session: Poster display - Cocktail
Resources:
Abstract
804 - Meta-analysis of four Phase 3 RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as 1st Line Endocrine Therapy for HR+ Advanced Breast Cancer
Presenter: John Robertson
Session: Poster display - Cocktail
Resources:
Abstract
1154 - Estimation of efficacy and safety of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in recurrent or metastatic breast cancer patients
Presenter: Sung Soo Kang
Session: Poster display - Cocktail
Resources:
Abstract